Attenuation of neurovirulence, biodistribution, and shedding of a poliovirus:rhinovirus chimera after intrathalamic inoculation in macaca fascicularis

Journal of Virology

Volumn 86, Issue 5, 2012, Pages 2750-2759

  Dobrikova, Elena Y ^a   Goetz, Christian ^a   Walters, Robert W ^a   Lawson, Sarah K ^a   Peggins, James O ^b   Muszynski, Karen ^b   Ruppel, Sheryl ^b   Poole, Karyol ^b   Giardina, Steven L ^b   Vela, Eric M ^c   Estep, James E ^c   Gromeier, Matthias ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c BATTELLE MEMORIAL INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NECL 5 PROTEIN; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL; CELL KILLING; CENTRAL NERVOUS SYSTEM; CHIMERA; CONTROLLED STUDY; CYTOTOXICITY; FEMALE; HISTOPATHOLOGY; IMMUNE RESPONSE; INOCULATION; MACACA FASCICULARIS; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; POLIOMYELITIS VIRUS; PRIORITY JOURNAL; PROTEIN SYNTHESIS; RHINOVIRUS; SEROTYPE; SYMPTOMATOLOGY; TRANSLATION INITIATION; UPREGULATION; VIRUS ATTENUATION; VIRUS CARCINOGENESIS; VIRUS CELL TRANSFORMATION; VIRUS REPLICATION; VIRUS SHEDDING; VIRUS VIRULENCE; ZONA LIMITANS INTRATHALAMICA;

ANIMALS; ANTIBODIES, VIRAL; CELL LINE; CHIMERA; DISEASE MODELS, ANIMAL; HUMANS; MACACA FASCICULARIS; POLIOMYELITIS; POLIOVIRUS; RHINOVIRUS; TISSUE DISTRIBUTION; VIRULENCE; VIRUS SHEDDING;

ANIMALIA; MACACA FASCICULARIS; POLIOVIRUS; PRIMATES; RHINOVIRUS;

EID: 84857880081     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.06427-11     Document Type: Article

References (48)

1. Andeweg AC, Bestebroer TM, Huybreghs M, Kimman TG, de Jong JC. 1999. Improved detection of rhinoviruses in clinical samples by using a newly developed nested reverse transcription-PCR assay. J. Clin. Microbiol. 37:524-530.
2. Bodian D. 1955. Emerging concept of poliomyelitis infection. Science 122:105-108.
3. Bodian D, Howe HA. 1945. Non-paralytic poliomyelitis in the chimpanzee. J. Exp. Med. 81:255-274.
4. Boone EJ, Albrecht P. 1983. Conventional and enhanced plaque neutralization assay for polio antibody. J. Virol. Methods 6:193-202.
5. Campbell SA, Lin J, Dobrikova EY, Gromeier M. 2005. Genetic determinants of cell type-specific poliovirus propagation in HEK 293 cells. J. Virol. 79:6281-6290.
6. Castriconi R, et al. 2009. NK cells recognize and kill human glioblastoma cells with stem cell-like properties. J. Immunol. 182:3530-3539.
7. Clark PF, Schindler J. 1932. Passage of poliomyelitis virus through the intestinal tract. J. Prev. Med. 6:47-58.
8. de Breyne S, Yu Y, Unbehaun A, Pestova TV, Hellen CU. 2009. Direct functional interaction of initiation factor eIF4G with type 1 internal ribosomal entry sites. Proc. Natl. Acad. Sci. U. S. A. 106:9197-9202.
9. Dobrikov M, Dobrikova E, Shveygert M, Gromeier M. 2011. Phosphorylation of eukaryotic translation initiation factor 4G1 (eIF4G1) by protein kinase C- α regulates eIF4G1 binding to Mnk1. Mol. Cell. Biol. 31:2947-2959.
10. Dobrikova EY, et al. 2008. Recombinant oncolytic poliovirus eliminates glioma in vivo without genetic adaptation to a pathogenic phenotype. Mol. Ther. 16:1865-1872.
11. Dobrikova EY, Grisham RN, Kaiser C, Lin J, Gromeier M. 2006. Competitive translation efficiency at the picornavirus type 1 internal ribosome entry site facilitated by viral cis and trans factors. J. Virol. 80: 3310-3321.
12. Evans DM, et al. 1985. Increased neurovirulence associated with a single nucleotide change in a noncoding region of the Sabin type 3 poliovaccine genome. Nature 314:548-550.
13. Florez de Sessions P, Dobrikova E, Gromeier M. 2007. Genetic adaptation to untranslated region-mediated enterovirus growth deficits by mutations in the nonstructural proteins 3AB and 3CD. J. Virol. 81:8396-8405.
14. Goetz C, Everson RG, Zhang LC, Gromeier M. 2010. MAPK signalintegrating kinase controls cap-independent translation and cell typespecific cytotoxicity of an oncolytic poliovirus. Mol. Ther. 18:1937-1946.
15. Gromeier M, Alexander L, Wimmer E. 1996. Internal ribosomal entry site substitution eliminates neurovirulence in intergeneric poliovirus recombinants. Proc. Natl. Acad. Sci. U. S. A. 93:2370-2375.
16. Gromeier M, Bossert B, Arita M, Nomoto A, Wimmer E. 1999. Dual stem-loops within the poliovirus internal ribosomal entry site control neurovirulence. J. Virol. 73:958-964.
17. Gromeier M, Lachmann S, Rosenfeld MR, Gutin PH, Wimmer E. 2000. Intergeneric poliovirus recombinants for the treatment of malignant glioma. Proc. Natl. Acad. Sci. U. S. A. 97:6803-6808.
18. Harashima A, Guettouche T, Barber GN. 2010. Phosphorylation of the NFAR proteins by the dsRNA-dependent protein kinase PKR constitutes a novel mechanism of translational regulation and cellular defense. Genes Dev. 24:2640-2653.
19. Horie H, et al. 2001. Analysis of the accumulation of mutants in Sabin attenuated polio vaccine viruses passaged in Vero cells. Vaccine 19:1456-1459.
20. Howe HA, Bodian D. 1940. Untreated human stools as a source of poliomyelitis virus. J. Infect. Dis. 66:198-201.
21. Jang SK, et al. 1988. A segment of the 5' nontranslated region of encephalomyocarditis virus RNA directs internal entry of ribosomes during in vitro translation. J. Virol. 62:2636-2643.
22. Kafasla P, Morgner N, Robinson CV, Jackson RJ. 2010. Polypyrimidine tract-binding protein stimulates the poliovirus IRES by modulating eIF4G binding. EMBO J. 29:3710-3722.
23. Kawamura N, et al. 1989. Determinants in the 5' noncoding region of poliovirus Sabin 1 RNA that influence the attenuation phenotype. J. Virol. 63:1302-1309.
24. Lowe B, Avila HA, Bloom FR, Gleeson M, Kusser W. 2003. Quantitation of gene expression in neural precursors by reverse-transcription polymerase chain reaction using self-quenched, fluorogenic primers. Anal. Biochem. 315:95-105.
25. Melnick JL. 1946. The recovery of poliomyelitis virus from the stools of experimentally infected monkeys and chimpanzees. J. Immunol. 53:277-290.
26. Merrill MK, et al. 2004. Poliovirus receptor CD155-targeted oncolysis of glioma. Neuro-Oncology 6:208-217.
27. Merrill MK, Dobrikova EY, Gromeier M. 2006. Cell-type-specific repression of internal ribosome entry site activity by double-stranded RNAbinding protein 76. J. Virol. 80:3147-3156.
28. Merrill MK, Gromeier M. 2006. The double-stranded RNA binding protein 76:NF45 heterodimer inhibits translation initiation at the rhinovirus type 2 internal ribosome entry site. J. Virol. 80:6936-6942.
29. Minor PD, Macadam AJ, Stone DM, Almond JW. 1993. Genetic basis of attenuation of the Sabin oral poliovirus vaccines. Biologicals 21:357-363.
30. Neplioueva V, Dobrikova EY, Mukherjee N, Keene JD, Gromeier M. 2010. Tissue type-specific expression of the dsRNA-binding protein 76 and genome-wide elucidation of its target mRNAs. PLoS One 5:e11710.
31. Nomoto A, Lee YF, Wimmer E. 1976. The 5' end of poliovirus mRNA is not capped with m7G(5')ppp(5')Np. Proc. Natl. Acad. Sci. U. S. A. 73: 375-380.
32. Nomoto A, et al. 1982. Complete nucleotide sequence of the attenuated poliovirus Sabin 1 strain genome. Proc. Natl. Acad. Sci. U. S. A. 79:5793-5797.
33. Ochs K, et al. 2003. Impaired binding of standard initiation factors mediates poliovirus translation attenuation. J. Virol. 77:115-122.
34. Pelletier J, Sonenberg N. 1988. Internal initiation of translation of eukaryotic mRNA directed by a sequence derived from poliovirus RNA. Nature 334:320-325.
35. Pyronnet S, et al. 1999. Human eukaryotic translation initiation factor 4G (eIF4G) recruits Mnk1 to phosphorylate eIF4E. EMBO J. 18:270-279.
36. Sabin AB. 1960. Oral, live poliovirus vaccine for elimination of poliomyelitis. Arch. Intern. Med. 106:5-9.
37. Sabin AB. 1956. Pathogenesis of poliomyelitis; reappraisal in the light of new data. Science 123:1151-1157.
38. Shveygert M, Kaiser C, Bradrick SS, Gromeier M. 2010. Regulation of eukaryotic initiation factor 4E (eIF4E) phosphorylation by mitogenactivated protein kinase occurs through modulation of Mnk1-eIF4G interaction. Mol. Cell. Biol. 30:5160-5167.
39. Sloan KE, et al. 2004. CD155/PVR plays a key role in cell motility during tumor cell invasion and migration. BMC Cancer 4:73.
40. Sloan KE, Stewart JK, Treloar AF, Matthews RT, Jay DG. 2005. CD155/ PVR enhances glioma cell dispersal by regulating adhesion signaling and focal adhesion dynamics. Cancer Res. 65:10930-10937.
41. Sutter RW, Cochi SL, Melnick JL. 1999. Live attenuated poliovirus vaccines, p 364-408. In Plotkin SA, OrensteinWA(ed), Vaccines, 3rd ed. W. B. Saunders, Philadelphia, PA.
42. Takai Y, Miyoshi J, Ikeda W, Ogita H. 2008. Nectins and nectin-like molecules: roles in contact inhibition of cell movement and proliferation. Nat. Rev. Mol. Cell. Biol. 9:603-615.
43. Toyoda H, Yin J, Mueller S, Wimmer E, Cello J. 2007. Oncolytic treatment and cure of neuroblastoma by a novel attenuated poliovirus in a novel poliovirus-susceptible animal model. Cancer Res. 67:2857-2864.
44. Walters RW, Bradrick SS, Gromeier M. 2010. Poly(A)-binding protein modulates mRNA susceptibility to cap-dependent miRNA-mediated repression. RNA. 16:239-250.
45. Wimmer E, Hellen CU, Cao X. 1993. Genetics of poliovirus. Annu. Rev. Genet. 27:353-436.
46. World Health Organization. 2002. Recommendations for the production and control of poliomyelitis vaccine (oral). World Health Organ. Tech. Rep. Ser. 910:1-104.
47. World Health Organization. 1990. Requirements for poliomyelitis vaccine (oral). World Health Organ. Tech. Rep. Ser. 800:30-86.
48. Yang X, et al. 2009. Evaluation of IRES-mediated, cell-type-specific cytotoxicity of poliovirus using a colorimetric cell proliferation assay. J. Virol. Methods 155:44-54.